|
|
|
|
|
Alendronate
drug data and news
Alendronate drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Alendronate | ||
| Brand Names/Synonyms | ALENDRONIC ACID; Acide Alendronique [Inn-French]; Acido Alendronico [Inn-Spanish]; Acidum Alendronicum [Inn-Latin]; Adronat; Alendronate; Alendronate Sodium; Alendronic Acid; Alendronic Acid [Ban:Inn]; Alendros; Arendal; CHEMBANK1709; Fosamax; MK 217; Onclast | ||
| Indication | For the treatment and prevention of osteoporosis in women and Paget's disease of bone in both men and women | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Alendronate, a second-generation bisphosphonate is the first member of a group of drugs which strengthens bone. Alendronate is used to reduce hypercalcemia in tumor-induced bone disease, to treat corticosteroid-induced osteoporosis and Paget's disease, and to prevent osteoporosis in postmenopausal women. | ||
| Mechanism Of Action | The action of Alendronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Alendronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass. | ||
| Alendronate News (When available) |
Cephalon Reports Outstanding Financial Results for 2005 Feb 14, 2006 Cell Therapeutics: hoping for a rich performance Feb 9, 2006 Early-Stage Biopharmaceuticals Firm Seeks New Funding Feb 13, 2006 Cephalon, Inc. Provides Update on Regulatory Status of NUVIGIL(TM) Feb 1, 2006 Cephalon, Inc. Provides Update on Regulatory Status of NUVIGIL(TM) Feb 1, 2006 Cephalon, Inc. Announces Agreements With Barr Laboratories, Inc. ... Feb 1, 2006 Cephalon, Inc. Announces Agreements With Barr Laboratories, Inc. ... Feb 1, 2006 Cell Therapeutics: hoping for a rich performance 09 Feb 2006 Cephalon, Inc. Provides Update on Regulatory Status of NUVIGIL Feb 2, 2006 Horst Witzel, Dr.-Ing., to Retire From Cephalon Board of Directors Jan 31, 2006 Cephalon, Inc. Provides Update on Regulatory Status of SPARLON(TM) Jan 25, 2006 Horst Witzel, Dr.-Ing., to Retire From Cephalon Board of Directors Jan 31, 2006 Cephalon, Inc. Announces Agreements With Barr Laboratories, Inc. ... Feb 1, 2006 Cephalon, Inc. Announces Agreements With Barr Laboratories, Inc. ... Feb 1, 2006 Scientific Advances on Three Lead Cephalon Oncology Compounds to ... Dec 8, 2005 Scientific Advances on Three Lead Cephalon Oncology Compounds to ... Dec 8, 2005 Cephalon Could Have A Tough Year In 2007 Dec 8, 2005 Cell Therapeutics, Inc. Reports Third Quarter 2005 Financial ... Nov 14, 2005 Cell Therapeutics 3Q Loss Narrows Nov 14, 2005 Women to be focus of tests on cancer drug Nov 15, 2005 Cephalon, Inc. Announces Agreement to Acquire Zeneus Holdings ... Dec 5, 2005 Cephalon expected to buy British drugmaker Dec 6, 2005 Cell Therapeutics cites loss Nov 14, 2005 TABLE-Cell Therapeutics Q3 net loss narrows Nov 14, 2005 Source: Cephalon, Inc.; Zeneus Holdings Limited Dec 5, 2005 BMS' dasatinib expected to rival Gleevec Nov 21, 2005 Shedding workers Sep 26, 2005 FDA Extends PDUFA Date for VIVITREX(R) to December 30, 2005 ... Sep 20, 2005 Cephalon Receives FDA Approval to Market Sugar-Free Formulation of ... Sep 12, 2005 Cephalon Receives FDA Approval to Market Sugar-Free Formulation of ... Sep 12, 2005 | ||
| Dosage Forms | 10 mg (Rx) Fosamax lactose 40 mg (Rx) Fosamax lactose | ||
| Drug_Category | Antiresorptives; Bisphosphonates; Antihypocalcemic Agents; ATC:M05BA04 | ||
| Absorption | Relative to an intravenous (IV) reference dose, the mean oral bioavailability of alendronate in women was 0.7% for doses ranging from 5 to 40 mg when administered after an overnight fast and two hours before a standardized breakfast. Oral bioavailability of the 10 mg tablet in men (0.59%) was similar to that in women (0.78%) when administered after an overnight fast and 2 hours before breakfast. | ||
| Interactions | Intravenous ranitidine was shown to double the bioavailability of oral alendronate. The clinical significance of this increased bioavailability and whether similar increases will occur in patients given oral H2-antagonists is unknown; no other specific drug interaction studies were performed. Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate. | ||
| Toxicity | Alendronate can damage the esophagus both by toxicity from the medication itself and by nonspecific irritation secondary to contact between the pill and the esophageal mucosa, similar to other cases of "pill esophagitis." | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | (4-amino-1-hydroxy-1-phosphono-butyl)phosphonic acid | ||
| Chemical Formula | C4H13NO7P2 | ||
| Molecular Weight | 249.096 g/mol | ||
| Smiles String | C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN | ||
| Melting Point | 233 - 235 °C | ||
| Water Solubility | 1mg/L | ||
| State | Fine white powder | ||
| LogP/Hphobicity | -3.198 | ||
| Isoelectric Point | 2.72 | ||
| Biotransformation | There is no evidence that alendronate is metabolized in humans or animals | ||
| Half Life | >10 years | ||
| Protein Binding [%] | 78% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Alendronate.html http://www.rxlist.com/cgi/generic/alendron.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00561 | ||
| CAS Registry Number | 66376-36-1 | ||
| KEGG Compound ID | C07752 | ||
| PubChem ID | SID:9954 | ||
| PharmGKB ID | PA448082 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2261715 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |